Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There are various regimens for thromboprophylaxis after hip replacement. Low-molecular-weight heparins such as enoxaparin predominantly inhibit factor Xa but also inhibit thrombin to some degree. Orally active, specific factor Xa inhibitors such as apixaban may provide effective thromboprophylaxis with a lower risk of bleeding and improved ease of use. METHODS: In this double-blind, double-dummy study, we randomly assigned 5407 patients undergoing total hip replacement to receive apixaban at a dose of 2.5 mg orally twice daily or enoxaparin at a dose of 40 mg subcutaneously every 24 hours. Apixaban therapy was initiated 12 to 24 hours after closure of the surgical wound; enoxaparin therapy was initiated 12 hours before surgery. Prophylaxis was continued for 35 days after surgery, followed by bilateral venographic studies. The primary efficacy outcome was the composite of asymptomatic or symptomatic deep-vein thrombosis, nonfatal pulmonary embolism, or death from any cause during the treatment period. Patients were followed for an additional 60 days after the last intended dose of study medication. RESULTS: A total of 1949 patients in the apixaban group (72.0%) and 1917 patients in the enoxaparin group (71.0%) could be evaluated for the primary efficacy analysis. The primary efficacy outcome occurred in 27 patients in the apixaban group (1.4%) and in 74 patients in the enoxaparin group (3.9%) (relative risk with apixaban, 0.36; 95% confidence interval [CI], 0.22 to 0.54; P<0.001 for both noninferiority and superiority; absolute risk reduction, 2.5 percentage points; 95% CI, 1.5 to 3.5). The composite outcome of major and clinically relevant nonmajor bleeding occurred in 129 of 2673 patients assigned to apixaban (4.8%) and 134 of 2659 assigned to enoxaparin (5.0%) (absolute difference in risk, -0.2 percentage points; 95% CI, -1.4 to 1.0). CONCLUSIONS: Among patients undergoing hip replacement, thromboprophylaxis with apixaban, as compared with enoxaparin, was associated with lower rates of venous thromboembolism, without increased bleeding. (Funded by Bristol-Myers Squibb and Pfizer; ClinicalTrials.gov number, NCT00423319.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The WARFASA 309 and ASPIRE 318 trials compared aspirin, 100 mg daily, with placebo for secondary prevention of recurrent VTE for patients with an initial unprovoked event, and the pooled results of the 2 trials showed a decrease in recurrent VTE, as well as major vascular events, without an increased risk for clinically relevant bleeding. 309,315”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [318]
In the citing paper
“The investigation into the use of the lower doses of these 2 anticoagulants for secondary prevention was prompted by the desire to reduce the risk of bleeding, as well as the documented efficacy of the lower doses to prevent VTE after elective hip or knee arthroplasty. 317-321”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [318]
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationSCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Prevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · Chest · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,373
Self-citationPrevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Self-citationSCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Self-citationDabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Self-citationRivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800374 · Cited by 1,433
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
Lassen, M. R., Ageno, W., Borris, L. C., Lieberman, J. R., Rosencher, N., Bandel, T. J., Misselwitz, F., & Turpie, A. G. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa076016 · Cited by 1,295
Self-citation
Cited by
Items 601–700 of 780
Medical Management of Venous Thromboembolism: What the Interventional Radiologist Needs to Know
Kasthuri, R. S., & Key, N. S. (2012) · Seminars in Interventional Radiology · doi:10.1055/s-0032-1302445 · Cited by 2
Trois nouveaux anticoagulants disponibles en 2011: Dabigatran Etexilate, Rivaroxaban et Apixaban
Samama, M. M., & Gerotziafas, G. (2011) · Bio Tribune Magazine · doi:10.1007/s11834-011-0048-6 · Cited by 2
Thromboprophylaxie médicamenteuse en chirurgie
Godiér, A., Rosencher, N., & Samama, C. M. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.07.001 · Cited by 2
“[14] Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM.”
BackgroundMolina-Razavi, J. E., Safavi‐Naeini, P., & Razavi, M. (2016) · Texas Heart Institute Journal · doi:10.14503/thij-16-5920 · Cited by 2
Overview of the Direct Oral Anticoagulants
Skeik, N., Sethi, A. R., & Shepherd, M. F. (2017) · Journal of the Minneapolis Heart Institute Foundation · doi:10.21925/mplsheartjournal-d-16-00005 · Cited by 2
The case for extended thromboprophylaxis in medically hospitalised patients – not yet made
Cao, J., Lee, S. Y., Dunkley, S. M., Adams, M. R., & KEECH, A. C. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319836572 · Cited by 2
Meretskyi, V., & Meretska, I. (2019) · Klinicheskaia khirurgiia · doi:10.26779/2522-1396.2019.06.73 · Cited by 2
Drug-Induced Disorders and Dental Implant Treatment
Hsiao, C. Y., & Qing, H. (2019) · Springer eBooks · doi:10.1007/978-3-030-28557-9_8 · Cited by 2
Coagulation and Anticoagulants
Goubran, H. A., Bosch, M. J., & Stakiw, J. (2019) · Springer eBooks · doi:10.1007/978-3-030-25782-8_1 · Cited by 2
Nahornyj, E., Goutelle, S., Bourguignon, L., & de la Gastine, B. (2020) · Therapies · doi:10.1016/j.therap.2020.07.001 · Cited by 2
Zhang, D., Pan, L., Maimaitijuma, T., Liu, H., & Wu, H. (2021) · Journal of Healthcare Engineering · doi:10.1155/2021/5540834 · Cited by 2
RetractedFasano, A., & Sequeira, A. (2017) · Modeling, simulation & applications · doi:10.1007/978-3-319-60513-5_2 · Cited by 2
ORAL ANTICOAGULANTS IN THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS: FOCUS ON APIXABAN
Gilyarov, M. Y., & Константинова, Е. В. (2017) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2017-7-56-62 · Cited by 2
Clinical Implications of Co‐administering Apixaban with Key Interacting Medications
Favatella, N., Dalton, D., Byon, W., Merali, S. J., & Klem, C. (2024) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1446 · Cited by 2
“• stroke and systemic embolism (SE) risk reduction in patients with nonvalvular atrial fibrillation (NVAF) 4,5 • thromboprophylaxis in patients who have undergone elective hip or knee replacement surgery 6,7 • treatment of initial, as well as extended, prevention of recurrent, VTE.”
New anticoagulants in ambulatory anaesthesia
Samama, C. M. (2015) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000000357 · Cited by 2
Optimization for small volume of distribution leading to the discovery of apixaban
He, K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-817134-9.00023-4 · Cited by 1
Deruelle, P., Debalme, C., Garcia-Lebailly, K., Giusto, C. D., & Sentilhes, L. (2024) · Gynécologie Obstétrique Fertilité & Sénologie · doi:10.1016/j.gofs.2024.02.027 · Cited by 1
Загреков, В. И., Константинович, У. А., Vorontsov, A. K., Sapronova, N. G., Владимирович, Г. М., Lychagin, A. V., Апарцин, К. А., Zolotukhin, I. A., Lomakin, N. V., & Sychev, D. A. (2025) · Russian Journal of Cardiology and Cardiovascular Surgery · doi:10.17116/kardio202518051577 · Cited by 1
Functionalization of λ5-Phosphinines via metalation strategies
Rambaud, F., Fotie, B. T., Naumann, R., Heinze, K., & Didier, D. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01822-6 · Cited by 1
“Interestingly, we were able to isolate the phosphininyl-conjugates 3x-y of pharmaceutically-relevant moieties present in Apaxiban 27 and Elagolix 28 , as well as nucleoside-and galactal-derivatives 3z and 3aa .”
Zhu, Y.-F., Qian, H., Ma, J.-H., Shen, N.-N., & Li, W. (2026) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296251410933 · Cited by 1
“24 Large-scale, real-world studies are therefore needed to better characterize the incidence of VTE and adverse outcomes across different antithrombotic regimens.”
Culler, M. W., Lim, M. A., Telang, S. S., Palmer, R. C., Iyer, A., Chung, B., Lieberman, J. R., & Heckmann, N. D. (2026) · The Journal of Arthroplasty · doi:10.1016/j.arth.2026.04.017 · Cited by 1
Marušič, A. P., Kovačič, S., Mrhar, A., & Petrovič, D. (2014) · Slovenian Medical Journal · Cited by 1
Biggi, F., Randelli, F., Rocca, C. D., Imberti, D., Grossi, P., Landolfi, R., Palareti, G., & Prisco, D. (2013) · LO SCALPELLO-OTODI Educational · doi:10.1007/s11639-013-0047-3 · Cited by 1
Managing New Oral Anticoagulants in the Intensive Care Unit
Gass, J. A., & Weeks, P. A. (2013) · Critical Care Nursing Quarterly · doi:10.1097/cnq.0b013e3182a10f41 · Cited by 1
Shantsila, E., Apostolakis, S. Z., & Lip, G. Y. H. (2013) · doi:10.1007/978-1-908517-96-8_5 · Cited by 1
Idiopathic Venous Thromboembolism
Sinescu, C. J. (2013) · Springer eBooks · doi:10.1007/978-1-4471-4429-8_20 · Cited by 1
Novel Oral Anticoagulants for Stroke Prophylaxis and Venous Thromboembolism Prevention and Treatment
Alsayegh, L. G. (2015) · Journal of patient-centered research and reviews · doi:10.17294/2330-0698.1055 · Cited by 1
Venous thromboembolic disease.
Jaff, M. R. (2002) · PubMed · Cited by 1
New Drugs for Thromboprophylaxis: Apixaban, Dabigatran, Rivaroxaban
Ferrandis, R. (2012) · Springer eBooks · doi:10.1007/978-1-4471-4336-9_6 · Cited by 1
Mantovani, L. G., Minno, G. D., & Furneri, G. (2013) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v14i3.670 · Cited by 1
Practical Management of Anticoagulants in Family Medicine after Orthopedic Surgery
Toth, P. P. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2581 · Cited by 1
Lam, S. (2013) · Cardiology in Review · doi:10.1097/crd.0b013e318293d6e6 · Cited by 2
Khemasuwan, D., & Suramaethakul, N. (2012) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029612438957 · Cited by 2
Páramo, J. A. (2012) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(12)70485-7 · Cited by 1
Paje, D. G., & Kaatz, S. (2013) · Hospital Medicine Clinics · doi:10.1016/j.ehmc.2013.04.004 · Cited by 2
Apixaban for oral antithrombotic therapy: is a new era coming?
Zhang, Y. (2014) · Molecular and Cellular Therapies · doi:10.1186/2052-8426-2-4 · Cited by 1
“0001, respectively) without increased bleeding [3,4].”
Squizzato, A. (2012) · Scientifica · doi:10.6064/2012/502378 · Cited by 1
Galanis, T., & Merli, G. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-2203-7_4 · Cited by 2
Xabans as Direct Factor Xa Inhibitors
Sen, D. J. (2015) · Journal of Bioanalysis & Biomedicine · doi:10.4172/1948-593x.1000e127 · Cited by 1
“Apixaban has no direct effect on platelet aggregation, but by inhibiting factor Xa, it indirectly decreases platelet formation induced by thrombin [5].”
BackgroundBounhoure, J., Montastruc, J., & Vacheron, A. (2014) · Cited by 1
Nicolaides, A. N., Fareed, J., Kakkar, A. K., Comerota, A. J., Goldhaber, S. Z., Hull, R., Myers, K., Samama, M. M., Fletcher, J., Kalodiki, E., et al. (2013) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029612474840f · Cited by 2
“05).(175) Edoxaban is a new oral direct FXa inhibitor that is 10 000fold more selective for FXa than thrombin.”
BackgroundSelf-citationThromboprophylaxis in Orthopedic Surgery
Warwick, D. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-21148-0_5 · Cited by 1
Prevención de la enfermedad tromboembólica venosa en cirugía
Degirmenci, S.-E., Tacquard, C. A., & Steib, A. (2016) · EMC - Anestesia-Reanimación · doi:10.1016/s1280-4703(16)79274-7 · Cited by 1
A Review on the Reversal of the Old and New Anticoagulants
Bailey, A. M., Blackburn, M. C., Crowley, J. M., Horn, K. S., Schultz, A. E., & Baker, S. N. (2016) · Advanced Emergency Nursing Journal · doi:10.1097/tme.0000000000000123 · Cited by 2
The Direct Oral Anticoagulants
Garcia, D. A., Crowther, M. A., & Ageno, W. (2016) · Wiley eBooks · doi:10.1002/9781118344729.ch18 · Cited by 1
Ordóñez, J., & Palacios, A. U. (2016) · Revista Colombiana de Ortopedia y Traumatología · doi:10.1016/j.rccot.2016.11.007 · Cited by 1
New Oral Anticoagulants: General Features and Review of Pivotal Clinical Trials
Jang, S.-W. (2016) · The Korean Journal of Helicobacter and Upper Gastrointestinal Research · doi:10.7704/kjhugr.2016.16.4.178 · Cited by 1
“심방세동과 정맥혈전증에 대한 3상 연구를 Table 2에 요약하 였다.(3-6,13-35)”
Direct-acting oral anticoagulants: An overview
Salem, H. (2017) · Saudi Journal of Medicine and Medical Sciences · doi:10.4103/sjmms.sjmms_83_17 · Cited by 2
Winocour, J. S., Kaoutzanis, C., Grotting, J. C., & Higdon, K. K. “. (2018) · Advances in Cosmetic Surgery · doi:10.1016/j.yacs.2018.02.018 · Cited by 1
Epidemiology and prevention of deep vein thrombosis
Castellucci, L. A., & Wells, P. S. (2014) · doi:10.2217/fmeb2013.13.151 · Cited by 1
Russian Experience in Rational Thromboprophylaxis in Traumatology and Orthopaedics
Фирсов, С. А., Levshin, A. G., & Павлович, М. Р. (2015) · N N Priorov Journal of Traumatology and Orthopedics · doi:10.17816/vto201522236-42 · Cited by 1
Broadbent, E. K., Lewin, A. R., Sylvester, K. W., Whitfield, B. A., & Knowles, D. M. (2019) · Journal of Pharmacy and Pharmacology · doi:10.17265/2328-2150/2019.03.001 · Cited by 1
“Bleeding event rates were also lower than those found in other studies, although this was likely due to the smaller enrollment numbers in this study [3, 8-13].”
BackgroundResultInfluentialGlassberg, M. B. (2017) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/c42y-0r27 · Cited by 1
Prise en charge d’une allergie à l’héparine : un case report et une revue de la littérature
Pelsez-Rouillé, A., Gondé, H., Pfister, G. D., Varin, R., Duchez, V. L. C., & Billoir, P. (2020) · Revue française d'allergologie · doi:10.1016/j.reval.2020.02.230 · Cited by 1
Rivas, L., Scully, R. D., Ju, T., DeBritz, J., & Sarani, B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-56724-4.00034-4 · Cited by 1
Venous Thromboembolism and Orthopedic Surgery
Bass, A. R. (2020) · Springer eBooks · doi:10.1007/978-3-030-35570-8_24 · Cited by 1
Biswas, S., Sasaki, J., & Braunfeld, M. Y. C. (2014) · Springer eBooks · doi:10.1007/978-1-4614-8948-1_24 · Cited by 1
[New oral anticoagulants: emerging clinical data and role of the primary care physician].
Motte, S. (2011) · PubMed · Cited by 1
Apixaban vs. Enoxaparin after Hip Replacement
Jameson, S. S., Sanders, R. D., & Reed, M. R. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1100733 · Cited by 1
Prandoni, P., & Ageno, W. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-01-0053 · Cited by 1
“ADVANCE 3 (9) Apixaban 12–24 hours 32–38 days All DVT + PE + death Proximal DVT + PE + VTE death Fatal bleed; intramuscular bleed with the compartment syndrome; bleed in the operated joint leading to re-operation; bleed in a critical site; clinically overt bleed associated with at least 2 g/dL fall in haemoglobin or l…”
BackgroundOutpatient Anticoagulant Therapy
Ansell, J. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2296-9.00039-7 · Cited by 2
Tafur, A. J., Caprini, J. A., & Arcelus, J. I. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2016.10.014 · Cited by 1
Weitz, J. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737039605.793578448 · Cited by 1
Nouveaux anticoagulants : ont-ils déjà une place en oncologie ?
Dicato, M. A., & Plawny, L. (2012) · ONCOLOGIE · doi:10.1007/s10269-012-2232-z
“Les études ADVANCE II et III, sur lesquelles est basée l’AMM, ne comportent pas d’analyse de sousgroupe permettant d’élargir l’indication à des patients atteints de cancer [16,17].”
BackgroundOral Direct Thrombin Inhibitors and Oral Factor Xa Inhibitors
Husted, S., & Wallentin, L. C. (2012) · Wiley eBooks · doi:10.1002/9781118410875.ch12
Agnelli, G. (2011) · Reviews in Health Care · doi:10.7175/rhc.v2i1s.54
Prevention of Venous Thromboembolism: An Evidence-Based Approach to Thromboprophylaxis
Piazza, G., Hohlfelder, B., & Goldhaber, S. Z. (2015) · Springer eBooks · doi:10.1007/978-3-319-20843-5_13
Prophylaxis for deep venous thrombosis and pulmonary embolism in surgery
Galanis, T., & Merli, G. J. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9780511920660.025
Antithrombotic Therapy in Non–ST‐Segment Elevation Acute Coronary Syndromes
Vlachojannis, G. J., Kunadian, V., Sweeny, J. M., & Mehran, R. (2012) · Wiley eBooks · doi:10.1002/9781118410875.ch15
Hainaut, P. (2012) · PubMed · doi:10.2143/acb.67.6.2062702
New oral anticoagulants and venous thromboembolic disease
Yannoutsos, A., Jeunne, C. L., Samama, C. M., & Blacher, J. (2012) · Sang thrombose vaisseaux · doi:10.1684/stv.2012.0685
Novedades en anticoagulación. ¿Nos olvidamos ya de la heparina y las antivitaminas K? Sí
Blanco-Molina, Á. (2012) · Revista Clínica Española · doi:10.1016/s0014-2565(12)70010-3 · Cited by 2
Stroke Prevention in Atrial Fibrillation
Prabhakaran, A., & Michota, F. A. (2013) · Current Emergency and Hospital Medicine Reports · doi:10.1007/s40138-013-0013-7
“5 mg apixaban twice daily was found to be superior to 40 mg enoxaparin daily, but had similar efficacy when used with enoxaparin at a twice daily dosing of 30 mg [33–35].”
MethodRosencher, N., Zufferey, P. J., Laporte, S., & Mismetti, P. (2011) · Clinical Investigation · doi:10.4155/cli.11.39
Amin, A., & Langer, J. (2012) · Orthopedic Research and Reviews · doi:10.2147/orr.s25081
“4% of the apixaban group achieved the primary efficacy outcome.(26) Major bleed during the treatment period occurred in 0.”
Eerenberg, E. S., & Middeldorp, S. (2013) · Huisarts en Wetenschap · doi:10.1007/s12445-013-0180-5 · Cited by 1
Recomendaciones de SBA para la seguridad en la anestesia regional en uso de anticoagulantes
Fonseca, N. M., de Anestesiologia, S. B., Alves, R. R., & Pontes, J. P. J. (2013) · Brazilian Journal of Anesthesiology (Edicion en Espanol) · doi:10.1016/j.bjanes.2013.04.010
Labrador, J., & González-Porras, J.-R. (2014) · Angiología · doi:10.1016/j.angio.2014.04.007 · Cited by 2
Marija, M., Aleksandra, N., Divac, T., Milojević, P. S., & Nenezić, D. (2012) · Medicinski casopis · doi:10.5937/mckg46-1612
Apixaban (Eliquis®) : nouvel anticoagulant oral
Fourcade, M. (2012) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/s1261-694x(12)70406-6
Amin, A. (2012) · Hospital Practice · doi:10.3810/hp.2012.08.986
SECOT consensus on thromboembolisms in knee and hip replacement surgery
Castellet, E., Peidro, L., & Otero, R. (2013) · Revista Española de Cirugía Ortopédica y Traumatología · doi:10.1016/j.recote.2013.04.005
Estado actual de la anticoagulación. Nuevas estrategias preventivas y terapéuticas
Páramo, J. A. (2013) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(13)70690-5
Venous Thromboembolism Prophylaxis in Total Knee Arthroplasty and Total Hip Arthroplasty
Locke, C. F. S., & Moreland, C. J. (2012) · Hospital Medicine Clinics · doi:10.1016/j.ehmc.2012.08.002
Novel approaches to upper gastrointestinal conditions: a focus on bleeding and malignancy
Holster, I. L. (2014) · RePub (Erasmus University Rotterdam) · Cited by 1
Complications of hip and knee replacement surgery: a pharmaco-epidemiological approach
Lalmohamed, A. (2014) · Research Publications (Maastricht University)
¿Qué aportan los nuevos anticoagulantes en la prevención del tromboembolismo venoso y arterial?
Dalmau, F. G.-B. (2014) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2014.03.001 · Cited by 1
Pharmacotherapy of deep-venous thrombosis: current status and future perspective
Squizzato, A., Rancan, E., & Dentali, F. (2011) · Clinical Investigation · doi:10.4155/cli.11.75
Management of hemorrhagic complications associated with antithrombotic therapy
Majeed, A. (2014) · Figshare
Análise custo-efectividade dos novos anticoagulantes orais
Ferreira, J. P. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Approaches to the Prophylaxis and Treatment of Venous and Cardiac Thromboembolic Disease
Dittus, C. E., & Ansell, J. (2012) · Springer eBooks · doi:10.1007/978-1-4471-4297-3_5
Pipeline Preview 2011 A summary of the pharmaceutical pipeline
Ousterhout, M. (2011)
Summary Review Newer Oral Anticoagulant Drugs
Carson, S., Selph, S., Thakurta, S., & McDonagh, M. S. (2013)
Ousterhout, M. (2011)
Venous Thromboembolism and Orthopedic Surgery
Bass, A. R. (2014) · Springer eBooks · doi:10.1007/978-1-4614-0100-1_19
Antikoagülasyonda Yeni Ajanlar
Keren, F., & ŞAHİN, Ö. B. (2014) · Malatya Turgut Özal University Institutional Repository
Joseph, D. E. (2013) · Springer eBooks · doi:10.1007/978-1-4614-9560-4_16
Whiteside, G., & Perry, C. (2011)
Prevention of venous thromboembolism (VTE) in ICU: an overview of newly developed anticoagulants
Iba, T., & Wada, H. (2012) · Journal of the Japanese Society of Intensive Care Medicine · doi:10.3918/jsicm.19.177
Metadata
- Authors
- Lassen, M. R., Gallus, A., Raskob, G. E., Pineo, G., Chen, D., & Ramirez, L. M.
- Affiliations
- University of Copenhagen (DK)
- South Australia Pathology (AU)
- University of Oklahoma Health Sciences Center (US)
- University of Calgary (CA)
- Bristol-Myers Squibb (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-12-23
- Volume
- 363
- Issue
- 26
- Pages
- 2487-2498
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2133686162
- Cited by
- 775
- References
- 35
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 32 · 2023: 18 · 2022: 25 · 2021: 33 · 2020: 34 · 2019: 39 · 2018: 41 · 2017: 39 · 2016: 62 · 2015: 66 · 2014: 67 · 2013: 121 · 2012: 102
- FWCI
- 76.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Murdoch University Research Portal (submittedVersion)
- Flinders Academic Commons (Flinders University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, enoxaparin, thromboprophylaxis, total hip arthroplasty, factor Xa inhibitors, low molecular weight heparin, deep vein thrombosis, pulmonary embolism, bleeding risk, venography, non-inferiority, postoperative thromboprophylaxis, oral anticoagulants, venous thromboembolism
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Anticoagulants, Double-Blind Method, Female, Hemorrhage, Humans, Injections, Subcutaneous, Male, Middle Aged, Postoperative Complications, Pyrazoles, Pyridones, Confidence Intervals, Treatment Outcome, Enoxaparin, Arthroplasty, Replacement, Hip, Venous Thromboembolism, Young Adult, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.